Clinical

Respiratory: NICE recommends new inhaled treatment for cystic fibrosis infection

In draft recommendations published today, NICE has recommended tobramycin dry powder for inhalation (Tobi Podhaler, Novartis) as an option for treating pseudomonas lung infection in people with cystic fibrosis.

The draft guidance recommends tobramycin if nebulised tobramycin is considered an appropriate treatment, that is, when nebulised colistimethate is contraindicated, not tolerated or has not produced an adequate clinical response; and, if the manufacturer provides tobramycin dry powder with the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS.

Read more at NICE.

Bookmark and Share

Post a Comment

Enter this security code

Submit Comment for Moderation